

Nizoral^{TRADEMARK}

(ketoconazole) tablets

over 5 million
prescriptions
world-wide.

**Oral medication
in antifungal therapy:**



Doctors and patients around the world are discovering the modern simplicity of Nizoral oral therapy. Common but often problematic fungal infections can now be treated effectively and elegantly.

Typically, in *Candida* vaginitis, 2 oral tablets once daily for 5 days is all it takes today to effectively cure the problem.

JANSSEN
PHARMACEUTICA

the drug discovery company

Prescribing Information

Presentation: white, flat, half scored uncoated tablets marked "Janssen" on one side and K/200 on the reverse. Each tablet contains 200 mg ketoconazole. **Uses:** Nizoral is an orally active antimycotic for the treatment in adults of vaginal candidosis, superficial and systemic mycoses including dermatophyte and yeast infections of the skin, hair and nails, yeast infections of the mouth and G.I. tract. Also maintenance treatment of systemic mycoses and chronic mucocutaneous candidosis and prophylaxis in "at risk" patients. In children: systemic mycoses and severe local infections where previous topical treatment has failed. **Side-effects, precautions, contra-indications:** contra-indicated in pregnancy. For maximal absorption Nizoral should be taken with meals. The use of agents which reduce gastric acidity (anti-cholinergic drugs, antacids, H₂-blockers) should be avoided and, if indicated, such drugs should be taken not less than two hours after Nizoral. Nausea, skin rash, headache and pruritus may occasionally be observed. Alterations in liver function tests have occurred in patients on ketoconazole, these changes may be transient. Cases of hepatitis have been reported with an incidence of about 1 per 10,000 patients. Some of these may represent an idiosyncratic adverse reaction to the drug. This should be borne in mind in patients on long-term therapy. If a patient develops jaundice or any symptoms suggestive of hepatitis, treatment with ketoconazole should be stopped. Mild asymptomatic increases of liver enzyme levels, on the other hand, do not necessitate discontinuation of the treatment. Ketoconazole, when given together with cyclosporin A results in increased blood levels of cyclosporin A. It is important that blood levels of cyclosporin A are monitored if the two drugs are given concomitantly. Ketoconazole 200 mg once daily produces a transient decrease in plasma levels of testosterone. During long-term therapy at this dose, testosterone levels are usually not significantly different from controls. In rare instances, gynecomastia has been reported.

APPROPRIATE TECHNOLOGY

Many of the difficulties of Third World medicine – the effects of poverty, overpopulation, and political unrest – are beyond the individual doctor's control; but what the western trained doctor practising in the developing world can and must do is to adapt his practice to compensate for the absence of sophisticated equipment, trained staff, and expensive drugs. It is wasteful for instance, to buy elaborate machinery if there is no reliable electricity supply to run it off, or order expensive orthopaedic aids from abroad when, with a bit of ingenuity, effective ones can be made from local materials. Written by doctors and technicians with first hand experience of the problems, *Appropriate Technology* is a guide to the sensible choice and use of resources, including the purchase and maintenance of operating theatre and laboratory equipment and specialist instruments for cardiology and gastroenterology. It sets out the practicalities of immunisation, rehydration, care and child health; sanitation; and the purchase and distribution of drugs, as well as describing workable methods of health education and the use of teaching aids; of maintaining medical records; and of conducting epidemiological surveys and research at low cost.


The British Medical Journal has subsidised this title to make this information widely available at as low a cost as possible.

Price: Inland £3.50;
Overseas £5.00/USA\$8.00
(Inland £3.00;
Overseas £4.50/USA\$7.00
to BMA members)

Despatched by air overseas

Please quote membership number

Payment must be enclosed with order



BOOKS FROM THE BMJ

Order from The Publishing Manager, British Medical Journal, BMA House, Tavistock Square,
London WC1H 9JR or any leading bookseller

Rocephin


ceftriaxone

Trade Mark

24-hour bactericidal power

third generation cephalosporin

«Rocephin»: 24-hour bactericidal power in serious infections



Comparison of concentrations in plasma and in extracellular fluid (skin blisters) after a single dose of 0.5 g ceftriaxone or 1 g cefotaxime (from Wise and Andrews¹).

«Rocephin» longer

Wise R, Andrews J.M.: A comparison of the bactericidal activity and tissue penetration of ceftriaxone, moxalactam and cefotaxime. *Eur J Clin Microbiol* 2, 505-508 (1983).

ROCHE

F. Hoffmann-La Roche & Co.
Limited Company, Basle, Switzerland

Full details on composition, indications, contraindications, dosage and precautions are available on request.